A survey of breakthrough therapy designations

被引：27

作者：

Aggarwal, Saurabh ^{[1
,2
]}

机构：

[1] Novel Hlth Strategies LLC, Bethesda, MD 20814 USA

[2] Inst Global Policy Res, Washington, DC USA

来源：

NATURE BIOTECHNOLOGY | 2014年 / 32卷 / 04期

关键词：

HEPATITIS-C; GENOTYPE; TREATMENT-NAIVE; DACLATASVIR; ASUNAPREVIR; INHIBITOR; INFECTION; RIBAVIRIN; TRIAL;

D O I：

10.1038/nbt.2864

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As of last month, 41 products have been granted breakthrough therapy designations by the US Food and Drug Administration-drugs against cancer, hepatitis C and monogenetic diseases predominate.

引用

页码：323 / 330

页数：8

共 38 条

[1] Targeted cancer therapies [J].

Aggarwal, Saurabh .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) :427-428

[2] What's fueling the biotech engine-2012 to 2013 [J].

Aggarwal, Saurabh Rob .

NATURE BIOTECHNOLOGY, 2014, 32 (01) :32-39

[3] What's fueling the biotech engine-2011 to 2012 [J].

Aggarwal, Saurabh .

NATURE BIOTECHNOLOGY, 2012, 30 (12) :1191-1197

[4] CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies [J].

Beers, Stephen A. ;

Chan, Claude H. T. ;

French, Ruth R. ;

Cragg, Mark S. ;

Glennie, Martin J. .

SEMINARS IN HEMATOLOGY, 2010, 47 (02) :107-114

[5] Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders [J].

Chayama, Kazuaki ;

Takahashi, Shoichi ;

Toyota, Joji ;

Karino, Yoshiyasu ;

Ikeda, Kenji ;

Ishikawa, Hiroki ;

Watanabe, Hideaki ;

McPhee, Fiona ;

Hughes, Eric ;

Kumada, Hiromitsu .

HEPATOLOGY, 2012, 55 (03) :742-748

[6] Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies [J].

Chen, Jianmeng ;

Florian, Jeffry ;

Carter, Wendy ;

Fleischer, Russell D. ;

Hammerstrom, Thomas S. ;

Jadhav, Pravin R. ;

Zeng, Wen ;

Murray, Jeffrey ;

Birnkrant, Debra .

GASTROENTEROLOGY, 2013, 144 (07) :1450-U218

[7]

Chustecka Z., 2014, IBRUTINIB IMBRUVICA

[8]

Collins T.R., 2013, NEUROLOGY TODAY, V13, P34

[9] Novel Bruton's tyrosine kinase inhibitors currently in development [J].

D'Cruz, Osmond J. ;

Uckun, Fatih M. .

ONCOTARGETS AND THERAPY, 2013, 6 :161-176

[10] Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug [J].

Desmond, Ronan ;

Townsley, Danielle M. ;

Dumitriu, Bogdan ;

Olnes, Matthew J. ;

Scheinberg, Phillip ;

Bevans, Margaret ;

Parikh, Ankur R. ;

Broder, Kinneret ;

Calvo, Katherine R. ;

Wu, Colin O. ;

Young, Neal S. ;

Dunbar, Cynthia E. .

BLOOD, 2014, 123 (12) :1818-1825

← 1 2 3 4 →